Literature DB >> 3330491

Urinary tract infections complicating pregnancy.

F G Cunningham.   

Abstract

Urinary infections, with a spectrum from covert bacteriuria to severe pyelonephritis, commonly complicate pregnancy. Serious infections follow untreated silent bacteriuria in a fourth of cases, and routine screening can be justified in high-risk populations, particularly those from lower socioeconomic strata. Despite an initial salutary response to a number of antimicrobial regimens, covert bacteriuria recurs in one-third of treated women whose risk of pyelonephritis remains at 25%. Acute cystitis may be unrelated to these other infections and responds readily to a number of regimens; however, single-dose therapy is not recommended since early pyelonephritis can be mistaken for uncomplicated cystitis. Pyelonephritis is the most common severe bacterial infection complicating pregnancy. These women are frequently quite ill, and hospitalization is recommended. Since 85% to 90% respond within 48 hours to intravenous fluids and antimicrobials, continued fever and evidence of sepsis after two or three days should prompt a search for underlying obstruction. Perhaps 20% of women with severe pyelonephritis develop complications that include septic shock syndrome or its presumed variants. These latter include renal dysfunction, haemolysis and thrombocytopaenia, and pulmonary capillary injury. In most of these women, continued fluid and antimicrobial therapy result in a salutary outcome, but there is occasional maternal mortality.

Entities:  

Mesh:

Year:  1987        PMID: 3330491     DOI: 10.1016/s0950-3552(87)80040-8

Source DB:  PubMed          Journal:  Baillieres Clin Obstet Gynaecol        ISSN: 0950-3552


  1 in total

1.  The peripheral whole-blood transcriptome of acute pyelonephritis in human pregnancya.

Authors:  Ichchha Madan; Nandor Gabor Than; Roberto Romero; Piya Chaemsaithong; Jezid Miranda; Adi L Tarca; Gaurav Bhatti; Sorin Draghici; Lami Yeo; Moshe Mazor; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Perinat Med       Date:  2014-01       Impact factor: 1.901

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.